Rigel Pharma (RIGL) Reports In-Line Q1 Loss
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $39.04 --0%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
STZ, NKE, PRGS, More
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
STZ, NKE, PRGS, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $5 million versus the consensus estimate of $4 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- MediaTek Inc. (2454:TT) (MDTKF) PT Raised to NT$5,800 at Nomura/Instinet
- UBS Downgrades EasyJet Plc. (EZJ:LN) (ESYJY) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
